FY2029 Earnings Forecast for TYRA Issued By Wedbush

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Tyra Biosciences in a research report issued on Friday, March 28th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.91) per share for the year. Wedbush currently has a “Outperform” rating and a $30.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share.

TYRA has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Trading Down 6.2 %

NASDAQ TYRA opened at $8.72 on Monday. Tyra Biosciences has a 12 month low of $8.66 and a 12 month high of $29.60. The stock has a 50-day simple moving average of $12.18 and a 200 day simple moving average of $16.13. The company has a market capitalization of $441.26 million, a PE ratio of -5.42 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total transaction of $65,325.48. Following the completion of the sale, the director now directly owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 21,998 shares of company stock valued at $344,818 over the last 90 days. 15.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences during the fourth quarter worth about $64,000. Finally, Wells Fargo & Company MN boosted its position in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.